+33(0)1 42 54 60 64 |

contact@welcomeurope.com

Login

JPND – Large scale analysis of OMICS data for drug-target finding in neurodegenerative diseases – 2023

JPND - Large scale analysis of omics data for drug-target finding in neurodegenerative diseases aiming at establishing a number of ambitious, innovative, multi-disciplinary and multinational collaborative research projects

2023-03-07
16.5 million euro
Close

Appeal framework

Institution European Commission
Sectors Health Research & Innovation
Beneficiaries Large company (> 250 employees) Research centre & university Smes & Start-Ups (< 249 Employees)
Regions Developing countries, European Economic Area, European Union, Northern America
Details

Eligible countries to the programme: Click here

Content reserved for subscribers

Register for free to access the content

Free access to all information

Priorities and funded actions

Objectives 

  • To establish a number of ambitious, innovative, multi-disciplinary and multinational collaborative research projects that seek to improve the understanding of the complex and multifactorial pathogenesis of neurodegenerative diseases by applying multi-OMICs and Big data approaches in order to generate useful information for the diagnosis, treatment, prognosis, and drug discovery of neurodegenerative diseases

Priorities

  • Priority 1: Alzheimer’s disease and other dementias
  • Priority 2: Parkinson’s disease and PD-related disorders
  • Priority 3: Prion diseases
  • Priority 4: Motor neuron diseases
  • Priority 5: Huntington’s disease
  • Priority 6: Spinocerebellar ataxia (SCA)
  • Priority 7: Spinal muscular atrophy (SMA)

Among financed actions

  • Using the potential from existing animal and cellular models and cohorts, including available data and biomaterial, for conducting large-scale OMICS approaches to unravel the interplay and interactions of molecules from multiple molecular levels driving disease pathogenesis
  • Better understanding the complex and multi-factorial mechanisms of disease onset and progression as well as the corresponding influencing factors
  • Translating the findings from Big Data analysis and multi-OMICS approaches to existing animal and cellular models, thereby enhancing the potential of these models
  • Identification of new drug targets or novel starting points for pharmacological interventions and prevention
  • Sharpening the current understanding of disease definition, thus leading to enhanced subclassification and better patient stratification
  • Identification of novel and validation of already established biomarkers

Additional information

  • This call for proposals is an open call for proposals
  • Initial duration of the call: 3 years

Eligibility

  • Be a universities or other higher education institutions
  • Be a non-university public or private research organisations
  • Be an hospital and other health and social care settings
  • Be a commercial companies, in particular small and mediumsize enterprises (SMEs)
  • Be a companies from outside the traditional medical sector (e.g. computing, artificial intelligence)
Financement
  • Amount of the call: 16.5 million euro

Test your eligibility

Need help with your public financing ?

Similar news

10 February 2023

Why work with a consultant for your European project?

Lire l'article

2 February 2023

How to identify European funds?

Lire l'article